Most Read Articles
24 Jun 2015
Persistent sleepless nights can take their toll on sufferers, and leave some insomniacs gasping for a caffeine hit just to get them through the morning slog.
01 Sep 2013
Centella asiatica methanol extract is a promising agent in skin care, a study shows.
14 Jan 2018
Patients with a first episode of Clostridium difficile infection (CDI) are likely to respond to treatment with fidaxomicin with no recurrences, a recent study has shown. On the other hand, those with prior CDI episodes are less likely to respond, especially with >1 prior episode, and more likely to recur, which suggests a greater clinical benefit of fidaxomicin earlier in the course of CDI.
01 Aug 2012

Proper use of family planning methods is the key to preventing unplanned preg­nancies. Despite the great effort spent in the research and development of contra­ceptive methods resulting in many new advances, none of the current methods is 100% effective. Emergency contraception (EC), also called ‘postcoital contraception’, is a back-up contraception adminis­tered to a woman after unprotected sexual intercourse (UPSI) or contraceptive failure, so as to prevent unplanned pregnancy. This may be indicated when unexpected intercourse has occurred without the use of any contraception, when there is a sus­pected potential failure of one’s regular contraceptive method (eg, condom break­age or slippage, missed dose of hormonal contraceptive, or potential failure of an intrauterine contraceptive device), or after sexual assault.

Tofacitinib shows therapeutic potential in ankylosing spondylitis

08 Feb 2017

Twice-daily tofacitinib 5 and 10 mg may produce greater improvements in signs, symptoms and objective endpoints of active ankylosing spondylitis (AS) in adults compared with placebo, according to data from a phase II study.

In addition, the drug has showed a 12-week safety profile that is similar to that reported in other indications.

A total of 207 patients were randomly assigned to one of the following treatment arms: tofacitinib 2 mg (n=52; mean age 41.8 years; 65.4 percent male), 5 mg (n=52; mean age 41.2 years; 75 percent male), 10 mg (n=52; mean age 41.6 years; 73.1 percent male) and placebo (n=51; mean age 41.9 years; 62.7 percent male). Treatment was given for 12 weeks, with a 4-week washout period.

The Assessment of SpondyloArthritis International Society 20 percent improvement (ASAS20) response rate at week 12 was used as the primary efficacy endpoint. Secondary endpoints were objective measures of disease activity, patient-reported outcomes and MRI of sacroiliac joints and spine. Safety was also assessed.

In an Emax model, ASAS20 response rate was 67.4 percent in the 10 mg arm, 63 percent in the 5 mg arm, 56 percent in the 2 mg arm, and 40.1 percent in the placebo arm.

Supportive normal approximation analysis found that the ASAS20 response rate with tofacitinib 5 mg was significantly higher than with placebo (80.8 vs 41.2 percent; p<0.001). Response rates were also greater with tofacitinib 2 and 10 mg, although the differences were not significant (51.9 and 55.8 percent, respectively).

There were general improvements observed in the secondary endpoints in the tofacitinib 5 and 10 mg arms vs placebo. Objective endpoints, including MRI, particularly showed clear dose response.

In terms of safety, adverse events showed no significant intergroup differences, without any unexpected safety findings.

Changes seen in dose-dependent laboratory outcomes returned close to baseline by week 16.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
24 Jun 2015
Persistent sleepless nights can take their toll on sufferers, and leave some insomniacs gasping for a caffeine hit just to get them through the morning slog.
01 Sep 2013
Centella asiatica methanol extract is a promising agent in skin care, a study shows.
14 Jan 2018
Patients with a first episode of Clostridium difficile infection (CDI) are likely to respond to treatment with fidaxomicin with no recurrences, a recent study has shown. On the other hand, those with prior CDI episodes are less likely to respond, especially with >1 prior episode, and more likely to recur, which suggests a greater clinical benefit of fidaxomicin earlier in the course of CDI.
01 Aug 2012

Proper use of family planning methods is the key to preventing unplanned preg­nancies. Despite the great effort spent in the research and development of contra­ceptive methods resulting in many new advances, none of the current methods is 100% effective. Emergency contraception (EC), also called ‘postcoital contraception’, is a back-up contraception adminis­tered to a woman after unprotected sexual intercourse (UPSI) or contraceptive failure, so as to prevent unplanned pregnancy. This may be indicated when unexpected intercourse has occurred without the use of any contraception, when there is a sus­pected potential failure of one’s regular contraceptive method (eg, condom break­age or slippage, missed dose of hormonal contraceptive, or potential failure of an intrauterine contraceptive device), or after sexual assault.